Every 8-K that Solesence, Inc. (SLSN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SLSN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SLSN filings page.
Solésence, Inc. (SLSN) reported that a review of inventory accounting for the quarter ended June 30, 2026 identified errors in its historical accounting for labor and overhead in inventories. The company used budget-based allocation methods that were not sufficiently supported and did not fully comply with ASC 330, Inventory, including capitalization limits and overhead allocation requirements.
As a result, Solésence concluded that inventories were overstated and cost of revenue misstated, which also affected gross profit, operating income (loss), income (loss) before income taxes, net income (loss), earnings (loss) per share, accumulated deficit, total stockholders’ equity and related disclosures for multiple prior periods. On August 17, 2026, the Audit Committee, Board of Directors and Executive Officers determined that consolidated financial statements as of and for the periods ended December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, September 30, 2025, December 31, 2025 and March 31, 2026 should no longer be relied upon and should be restated. Solésence expects to file amendments to its Annual Reports on Form 10-K for the years ended December 31, 2023, 2024 and 2025 and to its Quarterly Reports on Form 10-Q for the affected quarters, and has discussed these matters with its independent accountant.
Solésence, Inc. (SLSN) reported weaker financial results for the quarter ended June 30, 2026, while outlining strong order visibility and revenue expectations for the rest of the year. Net revenue for the second quarter was $15.3 million, down from $20.4 million a year earlier, largely due to a prior-year benefit from a major product launch and initial pipeline fill. Gross profit declined to $4.7 million with a 31% gross margin, versus $6.4 million and 32% in the second quarter of 2025. The company swung to a net loss of $158,000 from net income of $3.2 million, and adjusted EBITDA fell to $523,000 from $3.7 million.
Management also completed an evaluation of historical inventory costing allocation methodologies after filing a Form NT 10-Q and will restate related inventory valuation, emphasizing that these adjustments affect accounting presentation rather than cash generation or operations. As of August 17, 2026, shipped and on-hand orders for 2026 totaled $64.9 million, up from $60.0 million at the same point in 2025. The company expects sequential improvement in the third quarter, projects approximately $35 million of revenue in the second half of 2026, and believes full-year 2026 revenue will exceed 2025.
Solésence, Inc., through its wholly owned subsidiary Solésence, LLC, entered into a Settlement Agreement and Release with Refy Beauty Ltd to resolve disputes over certain consumer care products previously sold to Refy. Solésence agreed to pay Refy the British Pound Sterling equivalent of $938,000 in twelve equal installments of $78,166.66, with the first payment due on August 5, 2026 and each subsequent payment due 30 days later. The parties also agreed to a six month exclusivity period for development of a new SPF product and potential negotiation of a new supply agreement. If a new supply agreement is executed, the final six scheduled installment payments would instead be credited toward purchases of the SPF product under that supply agreement.
Solésence, Inc. reported first quarter 2026 revenue of $13.0 million, down from $14.6 million a year earlier, as it invested in its Transform and Transcend operational initiative. Despite lower sales, gross profit was $3.3 million and gross margin improved to 26% from 23%.
The company posted a net loss of approximately $0.8 million for the quarter, compared with net income of about $0.08 million in 2025, and Adjusted EBITDA declined to $(0.1) million from $0.6 million. Management highlighted near-term profitability pressure from training and organizational restructuring, but expects efficiency gains and lower labor costs to support better results later in the year.
Solésence, Inc. announced that its Board of Directors appointed Marc James as a Class II independent director, effective April 24, 2026. He will serve for the remainder of the Class II term, ending at the 2026 Annual Meeting of Shareholders.
James joins the Board’s Audit and Finance, Compensation, and Nominating and Corporate Governance Committees. The company highlights his capital markets and strategic experience as support for its Transform & Transcend strategic initiative and long-term growth objectives.
Solésence, Inc. reported record full-year 2025 revenue of $62.1 million, up 19% from $52.3 million, as it expanded its SPF-infused beauty product portfolio. Despite higher sales, full-year gross margin fell to 26% from 31% and net income declined to $1.8 million from $4.2 million, reflecting higher operating costs.
In the fourth quarter, revenue was $12.5 million, roughly flat year over year, but gross margin improved to 27% from 22%, turning a net loss of $0.6 million in 2024’s quarter into net income of $0.2 million. The company highlighted its “Transform & Transcend” initiative, aimed at operational excellence, technology-driven market expansion, service model innovation, and global growth with brand partners, alongside adding 20 new brand partners and securing 16 new patents.
Solésence, Inc. disclosed details of a separation agreement with former CEO Jess Jankowski following his previously reported resignation as an officer. Under the agreement, effective December 2, 2025, Jankowski will receive severance pay totaling $366,912, accelerated vesting of all his outstanding stock options, and continued company-paid health insurance premiums under COBRA for the duration of the severance period. In return, he is providing a broad release of claims against the company and reaffirming obligations such as restrictive covenants and assistance in certain potential disputes. The separation agreement is filed as an exhibit to this report, with some portions redacted as confidential.
Solésence, Inc. filed a Form 8‑K to furnish information under Item 2.02 (Results of Operations and Financial Condition). The company reported that it issued a press release, which is attached as Exhibit 99.1 and incorporated by reference.
The filing also includes a “Solésence Third Quarter 2025 Conference Call Script” as Exhibit 99.2. These materials provide the company’s communications around its quarterly results, with the exhibits serving as the official source documents.
Solésence, Inc. entered a settlement agreement with Solarium Brands, LLC and A-Frame Brands, LLC to resolve disputes related to previously sold consumer care products. Under the agreement, Solarium will make a one-time settlement payment of $675,000 to Solésence on or before January 15, 2026.
The agreement finalizes a commercial dispute and provides for a defined payment to Solésence. The full agreement was filed with certain confidential portions redacted.
Solésence, Inc. announced leadership changes alongside new employment agreements for its top executives. Kevin Cureton, age 64, who has been Chief Operating Officer since 2019, has been appointed Chief Executive Officer and President, effective September 3, 2025. Former CEO and CFO Jess Jankowski will transition to serve as Board Advisor until his planned retirement on November 21, 2025.
Laura Riffner, age 53, was appointed Chief Financial Officer as of September 3, 2025. She brings prior CFO and finance leadership experience from Nagase America and Paxton/Patterson, and is a licensed Certified Public Accountant. Under their agreements, Mr. Cureton’s annual base salary will be not less than $367,000, Mr. Jankowski’s transition salary will be not less than $366,912 through retirement, and Ms. Riffner’s annual base salary will be not less than $270,000, with Cureton and Riffner eligible for bonuses and stock option grants under the company’s equity plan.
Solésence, Inc. reported the results of its Annual Meeting of Shareholders held on August 28, 2025. Shareholders representing 61,205,907 shares, or about 86.83% of the 70,481,945 shares outstanding as of July 21, 2025, were present or represented by proxy, providing a quorum.
Two director nominees were elected: R. Janet Whitmore received 55,548,531 votes for, with 1,019,946 votes withheld and 4,637,430 broker non-votes; Laura M. Beres received 55,853,069 votes for, with 715,408 votes withheld and 4,637,430 broker non-votes.
Shareholders approved the Company’s 2025 Equity Compensation Plan with 56,301,567 votes for, 207,542 votes against, 59,368 abstentions, and 4,637,430 broker non-votes. They also ratified the appointment of RSM US LLP as independent registered public accounting firm for fiscal year 2025, with 61,074,473 votes for, 122,447 votes against, and 8,987 abstentions.